Retatrutide vs Ozempic: How the Triple Agonist Stacks Up Against Semaglutide

Retatrutide and Ozempic represent two different generations of obesity and metabolic medicine, and the headline difference is straightforward: in trials, retatrutide has produced substantially more weight loss than semaglutide, the ingredient in Ozempic. Retatrutide averaged roughly 24% to 28% in studies, while semaglutide produces around 15%. The catch is availability. Ozempic (and its higher-dose obesity counterpart, Wegovy) is FDA approved and available today, while retatrutide is still investigational and not yet on the market as of 2026. So this is a comparison between a proven, available option and a promising one that’s still in trials.

First, a clarification on names

Ozempic is the brand name for semaglutide dosed for type 2 diabetes. The same molecule, at a higher dose, is sold as Wegovy for weight management. When people compare “retatrutide vs Ozempic,” they’re really comparing retatrutide against semaglutide. Retatrutide, by contrast, doesn’t have a brand name yet because it hasn’t been approved.

How they work differently

The core difference is how many hormone pathways each drug activates.

Semaglutide is a single-receptor GLP-1 agonist. It reduces appetite, slows stomach emptying, and helps regulate blood sugar. That mechanism has proven powerful and reshaped obesity treatment.

Retatrutide is a triple agonist, hitting GLP-1, GIP, and glucagon receptors. The glucagon component is thought to boost calorie burning and reduce liver fat, which may explain why retatrutide has driven larger weight loss in studies.

Weight loss compared

The clearest way to see the difference is side by side. Semaglutide’s benchmark comes from its pivotal obesity trial published in the New England Journal of Medicine in 2021, where the 2.4 mg dose produced an average weight loss of about 15% over 68 weeks. Retatrutide’s phase 2 trial reported about 24% at 48 weeks, and its phase 3 topline (TRIUMPH-1, announced in 2026) reported roughly 28% at the highest dose.

Side effects and trade-offs

Both drugs share the GLP-1 class side effect profile: gastrointestinal effects like nausea, vomiting, and diarrhea, mostly during dose escalation. Retatrutide’s trials suggest its rate of these effects may run somewhat higher, which fits the pattern that more aggressive weight loss often comes with more gastrointestinal burden. Retatrutide trials also noted a mild skin-sensation side effect at higher doses. More weight loss isn’t free, and tolerability matters as much as efficacy for staying on a medication long term.

Availability is the deciding factor right now

Consider a hypothetical patient weighing her options. If she wants to start treatment this year, retatrutide isn’t a real choice yet, because it can’t be prescribed outside trials. Semaglutide, on the other hand, is available and well established, with years of real-world use behind it. For most people making a decision today, the practical comparison isn’t “which is stronger on paper” but “which can I actually access and start safely now.”

Common questions

Will retatrutide replace Ozempic?

It’s too early to say. Retatrutide’s trial results are impressive, but approval, real-world safety data, cost, and access all shape what actually gets used. Semaglutide will remain widely used for the foreseeable future.

Is retatrutide worth waiting for?

That’s a personal decision, but waiting means going untreated in the meantime, which has its own health costs. Many people benefit from starting an available, effective option now rather than delaying for a drug that may be a year or more from approval.

Can I get semaglutide now?

Yes. Semaglutide is available through several channels, including compounded and brand options depending on your situation and what a provider determines is appropriate.

The bottom line

Retatrutide looks stronger than semaglutide on trial weight loss, but semaglutide has the decisive advantage of being here, proven, and prescribable today. If you’d rather act now than wait, you can compare your options with a provider through TrimRx’s quiz and find out what fits your health and goals.

This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved. Consult a healthcare provider before starting any medication. Individual results may vary.